Press Release: The May 2019: Policy & Medicine Compliance Update

If you are already a subscriber, click here for immediate access to this issue.

PRESS RELEASE
Contact: Thomas Sullivan
Phone: (202) 309-3507
Email: sales@lifescienceupdates.com
Website: www.lifescicompliance.com

WASHINGTON, DC USA -- PHARMA UPDATE NEWS SERVICE™ -- MAY 15, 2019: This month the Policy and Medicine Compliance Update is focusing on research. We have articles on research misconduct and real-world evidence which discuss two current and important research topics. We also have Part 2 of our series on compliance risk assessments, which focuses this month on data analytics. Finally, we round out the issue with updates on the drug pricing hearings and the latest case impacting qui tam litigation.

FEATURE ARTICLE

SCIENTIFIC INQUIRY OR LEGAL JEOPARDY? - RESEARCH MISCONDUCT COMPLIANCE AFTER THE DUKE SETTLEMENT
By Carolyn Greene, Staff Writer, Policy & Medicine Compliance Update
Tags: Research Misconduct, NIH, Duke, False Claims

RESEARCH

DATA IN THE "REAL WORLD" -- PRESENT DAY
By Dr. Seth B. Whitelaw, Editor, Policy & Medicine Compliance Update
Tags: Real-World Evidence, Real-World Data, Big Data, Research

OPERATIONS

ARE LIFE SCIENCE COMPANIES TRULY MANAGING COMPLIANCE RISKS? BECOMING DATA READY
By Jenny Bi, Manager at FRA, with contributions from Jenny McVey, Ph.D., Associate Director of Risk Strategy, Novo Nordisk, Inc.
Topic tags: RAMP, Risk Management, Data Analytics, Big Data

DRUG PRICING

CONGRESS ENTERS THE DRUG PRICING FRAY
By Gwendolyn Ball, Staff Writer for Policy & Medicine Compliance Update
Topic tags: Drug Pricing, Pricing Transparency, Congress, Hearings

QUI TAM LITIGATION

INTERMOUNTAIN HEALTHCARE VERSUS THE WHISTLEBLOWER: CHALLENGING THE TENTH CIRCUIT'S APPLICATION OF THE FALSE CLAIMS ACT
By Robert N. Wilkey, Esq., Senior Staff Writer for Life Science Compliance Update
Topic tags: Qui Tam, Intermountain, Medical Necessity, Pleadings